1. Home /
  2. Markets /
  3. Mergers and Acquisitions

Mergers and Acquisitions  

Who Might the Oil Majors Acquire Next After Chevron's Anadarko Deal?

A rundown of several oil companies that could soon be on the block.

These Exploration Names May Also Pop With Chevron, Anadarko Deal

This deal will certainly strengthen Chevron's position in the Permian Basin, while also adding to global reserves of both petroleum and LNG.

Anadarko Deal Rewards Shareholders Betting on the Beleaguered Stock in 2019

Anadarko is surging as its planned, $33 billion acquisition by Chevron recognizes its underlying value.

Goldilocks Conditions Spur Another Upside Market Breakout

A combination of good economic news and friendly central banks creates a positive environment and leaves bears frustrated.

Wynn Resorts Craps Out on Crown Resorts, but Will It Return to the Table?

Wynn aborted talks to acquire Australia's largest casino operator when word of the negotiations leaked, but observers think a deal still may happen.

Constellation Brands Stock Can Still Run Despite Downgrade

There is certainly too much to ignore about STZ for the majority of analysts.

3 Promising Small Biotech Stocks to Watch

I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.

Apple's News+ Service Is Reportedly Off to a Solid Start -- Tech Check

Apple's news and magazine subscription service reportedly amassed over 200,000 subscribers in its first 48 hours.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Better Homebuilder Buy: KB Home or Lennar?

Time to break down the best bet.

You Can't Spell Dislike Without DIS

How to play Disney's tumble after the close of the Fox deal.

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Activist Investor Looks to Pick Apart Marriott's Massive Portfolio

Does the MAR have too many brands? 'Absolutely not,' says CEO Sorenson.

Nvidia Addresses Needs for AI, Robotics Revolution With Mellanox Deal

With Nvidia's needs addressed, the stock is set to surge.

How to Play This Apple Upgrade, and Semiconductor Strength: Market Recon

Consolidation is driving growth in the semis, but tech-led strength is never a bad thing.

Jim Cramer: Nvidia's Mellanox Deal, and Apple Upgrade, Have Lifted the Semis

It signals the glut in chips may be done with, which is good news for most of the semiconductor names.

Barrick Gold Could Really Rally If It Can Break Above $14.13

Let's see if the charts are desirable.

I Like the Long Side of Bristol-Myers Squibb

Let's see what the charts and indicators look like.

Rules of Biotech Investing Change, and So Must Biotech Investors

One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

5 Companies Warren Buffett Should Buy or Invest in Now

Cash is a lazy asset, but the genesis of Berkshire's underperformance has been choosing the wrong investments.

Is General Electric Still a Decent Value Play?

Just because the stock is still down substantially from its all-time highs doesn't mean that it is still 'cheap'.

Larry Culp Showed Up at the Right Time for General Electric

The question for us though becomes is this, or when is, the right time for investors to create some value for themselves?

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Kraft Heinz Crashes to Lowest Level of Buffett Era

Shares of food giant are cratering as faith in management fades.

Chart of the Day: Is CVS Stock Too Cheap to Ignore?

Is CVS open to those seeking value?

Trump Administration Is No Friend to Pharmacy Benefit Managers Like CVS

Pharmacy Benefit Managers (PBMs) are in for some problems if proposed regulation is given approval.

Light Forecast From CVS Health Weakens Stock

CVS is losing value for investors.

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Jim Cramer: SunTrust-BB&T Merger Is About Digital Defense and Offense

Analysts need to recognize this shift in the banking markets.